Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.
Theresa Shao, MD
Advertisement
Articles by Theresa Shao, MD
Theresa Shao, MD, assistant professor of medicine, hematology and medical oncology, Icahn School of Medicine, Mount Sinai Medical Center, discusses managing toxicities associated with neratinib (Nerlynx) in patients with HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Shao on Managing Toxicity With Neratinib in HER2+ Breast CancerJanuary 15th 2019
Dr. Shao on Prognosis of Patients With HER2+ Breast CancerFebruary 21st 2019
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5